Literature DB >> 11141389

[Prognostic markers of progression to AIDS in infants vertically infected by human immunodeficiency virus type-1].

S Resino1, J M Bellón, D Gurbindo, J T Ramos, J Ruiz Contreras, M A Muñoz-Fernández.   

Abstract

BACKGROUND: To study the prognostic AIDS progression value of the percentage of CD4+, CD8+, and plasma viral load (VL) (copies/ml) in HIV-1-vertically infected children. PATIENTS AND
METHOD: We study a cohort of 115 HIV-1 infected children older than 12 months of age. The VL was quantified using standard molecular assay. CD4 and CD8 T lymphocytes were determined by flow cytometry.
RESULTS: The children with a median of VL > 4.5 log10 (p < 0.001) and percentage of CD8+ < 25% (p = 0.05) during follow-up, progressed faster to AIDS than children with a median of VL < 4.5 log10 and CD8 > 25%. The relative risk (RR) of AIDS progression was 7-fold higher in children with median VL above 4.5 log10. When considering VL as a continuous variable, risk of progression to AIDS is 3.5-fold higher for each increase of one log10 of VL. The percentage of CD8+ T-cells had a RR of AIDS progression of 0.95/% CD8+ at entry to the study and of 0. 19/% CD8+ during follow-up, indicating protection against progression to AIDS.
CONCLUSIONS: Our results indicate that each basal values at entry in the study and during the follow-up of the percentage of CD8+ and VL helps to determine the risk of AIDS progression in HIV-1-infected children. More interestingly, the use of the two predictive markers together had higher predictive value.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11141389     DOI: 10.1016/s0025-7753(00)71626-5

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Naïve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART.

Authors:  S Resino; J Navarro; J M Bellón; D Gurbindo; J A León; M A Muñoz-Fernández
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.